Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-0c9b965fc8d8b37db9d00845bddc1040"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-0c9b965fc8d8b37db9d00845bddc1040"/>
<resource>
<Composition>
<id value="composition-en-0c9b965fc8d8b37db9d00845bddc1040"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-0c9b965fc8d8b37db9d00845bddc1040"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-0c9b965fc8d8b37db9d00845bddc1040</b></p><a name="composition-en-0c9b965fc8d8b37db9d00845bddc1040"> </a><a name="hccomposition-en-0c9b965fc8d8b37db9d00845bddc1040"> </a><a name="composition-en-0c9b965fc8d8b37db9d00845bddc1040-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/01/195/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - liprolog</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/01/195/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp0c9b965fc8d8b37db9d00845bddc1040"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - liprolog"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet:</p><ol type="1"><li>What Liprolog is and what it is used for</li><li>What you need to know before you use Liprolog</li><li>How to use Liprolog</li><li>Possible side effects</li><li>How to store Liprolog</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What liprolog is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What liprolog is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Liprolog is used to treat diabetes. Liprolog works more quickly than normal human insulin because the insulin molecule has been changed slightly.</p><p>You get diabetes if your pancreas does not make enough insulin to control the level of glucose in your blood. Liprolog is a substitute for your own insulin and is used to control glucose in the long term. It works very quickly and lasts a shorter time than soluble insulin (2 to 5 hours). You should normally use Liprolog within 15 minutes of a meal.</p><p>Your doctor may tell you to use Liprolog as well as a longer-acting insulin. Each kind of insulin comes with another patient information leaflet to tell you about it. Do not change your insulin unless your doctor tells you to. Be very careful if you do change insulin.</p><p>Liprolog is suitable for use in adults and children.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take liprolog"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take liprolog"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do NOT use Liprolog</p><ul><li>if you think hypoglycaemia (low blood sugar) is starting. Further in this leaflet it tells you how to deal with mild hypoglycaemia (see Section 3: If you take more Liprolog than you need).</li><li>if you are allergic to insulin lispro or any of the other ingredients of this medicine (listed in section 6).</li></ul><p>Warnings and precautions<br/>If your blood sugar levels are well controlled by your current insulin therapy, you may not feel the warning symptoms when your blood sugar is falling too low. Warning signs are listed later in this leaflet. You must think carefully about when to have your meals, how often to exercise and how much to do. You must also keep a close watch on your blood sugar levels by testing your blood glucose often. A few people who have had hypoglycaemia after switching from animal insulin to human insulin have reported that the early warning symptoms were less obvious or different. If you often have hypoglycaemia or have difficulty recognising it, please discuss this with your doctor.</p><p>If you answer YES to any of the following questions, tell your doctor, pharmacist or diabetes nurse</p><ul><li>Have you recently become ill?</li><li>Do you have trouble with your kidneys or liver?</li><li></li></ul><p>Are you exercising more than usual? The amount of insulin you need may also change if you drink alcohol. You should also tell your doctor, pharmacist or diabetes nurse if you are planning to go abroad. The time difference between countries may mean that you have to have your injections and meals at different times from when you are at home. Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with pioglitazone and insulin experienced the development of heart failure. Inform your doctor as soon as possible if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema).</p><p>Skin changes at the injection site: The injection site should be rotated to prevent skin changes such as lumps under the skin. The insulin may not work very well if you inject into a lumpy area (See How to use Liprolog). Contact your doctor if you are currently injecting into a lumpy area before you start injecting a different area. Your doctor may tell you to check your blood sugar more closey, and to adjust your insulin or your other antidiabetic medications dose.</p><p>Other medicines and Liprolog Your insulin needs may change if you are taking<br/>the contraceptive pill,<br/>steroids,<br/>thyroid hormone replacement therapy,<br/>oral hypoglycaemics,<br/>acetyl salicylic acid,<br/>sulpha antibiotics,<br/>octreotide,<br/>beta2 stimulants (for example ritodrine, salbutamol or terbutaline),<br/>beta-blockers, or<br/>some antidepressants (monoamine oxidase inhibitors or selective serotonin reuptake inhibitors),<br/>danazol,<br/>some angiotensin converting enzyme (ACE) inhibitors (for example captopril, enalapril), and<br/>angiotensin II receptor blockers.</p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p>Pregnancy and breast-feeding Are you pregnant or thinking about becoming pregnant, or are you breast-feeding? The amount of insulin you need usually falls during the first three months of pregnancy and increases for the remaining six months. If you are breast-feeding, you may need to alter your insulin intake or diet. Ask your doctor for advice.</p><p>Driving and using machines Your ability to concentrate and react may be reduced if you have hypoglycaemia. Please keep this possible problem in mind in all situations where you might put yourself and others at risk (e.g. driving a car or operating machinery). You should contact your doctor about the advisability of driving if you have:</p><ul><li>frequent episodes of hypoglycaemia</li><li>reduced or absent warning signs of hypoglycaemia</li></ul><p>Liprolog contains sodium This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially sodium- free .</p></div>
</text>
</section>
<section>
<title value="3. How to take liprolog"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take liprolog"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always check the pack and the vial label for the name and type of the insulin when you get it from your pharmacy. Make sure you get the Liprolog that your doctor has told you to use.</p><p>Always use Liprolog exactly as your doctor has told you. Check with your doctor if you are not sure.</p><p>Dosage</p><ul><li>You should normally inject Liprolog within 15 minutes of a meal. If you need to, you can inject soon after a meal. But your doctor will have told you exactly how much to use, when to use it, and how often. These instructions are only for you. Follow them exactly and visit your diabetes clinic regularly.</li><li>If you change the type of insulin you use (for example from a human or animal insulin to a Liprolog product), you may have to take more or less than before. This might just be for the first injection or it may be a gradual change over several weeks or months.</li><li>Inject Liprolog under the skin. You should only inject it into a muscle if your doctor has told you to.</li></ul><p>Preparing Liprolog</p><ul><li>Liprolog is already dissolved in water, so you do not need to mix it. But you must use it only if it looks like water. It must be clear, have no colour and no solid pieces in it. Check each time you inject yourself.</li></ul><p>Injecting Liprolog</p><ul><li>First wash your hands.</li><li>Before you make an injection, clean your skin as you have been instructed. Clean the rubber stopper on the vial, but do not remove the stopper.</li><li>Use a clean, sterile syringe and needle to pierce the rubber stopper and draw in the amount of Liprolog you want. Your doctor or clinic will tell you how to do this. Do not share your needles and syringes.</li><li>Inject under the skin, as you were taught. Do not inject directly into a vein. After your injection, leave the needle in the skin for five seconds to make sure you have taken the whole dose. Do not rub the area you have just injected. Make sure you inject at least half an inch (1 cm) from the last injection and that you rotate the places you inject, as you have been taught. It doesn t matter which injection site you use, either upper arm, thigh, buttock or abdomen, your Liprolog injection will still work quicker than soluble human insulin.</li><li>Your doctor will tell you if you have to mix Liprolog with one of the human insulins. For example if you do need to inject a mixture, draw the Liprolog into the syringe before the long acting insulin. Inject the liquid as soon as you have mixed it. Do the same thing every time. You should not normally mix Liprolog with one of the mixtures of human insulins. You should never mix Liprolog with insulins produced by other manufacturers or animal insulins.</li><li>You must not administer Liprolog by the intravenous route. Inject Liprolog as your physician or nurse has taught you. Only your physician can administer Liprolog by the intravenous route. He will only do this under special circumstances such as surgery or if you are ill and your glucose levels are too high.</li></ul><p>Using Liprolog in an infusion pump</p><ul><li><p>Only certain CE-marked insulin infusion pumps may be used to infuse insulin lispro. Before infusing insulin lispro, the manufacturers instructions should be studied to ascertain the suitability or otherwise for the particular pump. Read and follow the instructions in the product literature supplied with the infusion pump.</p></li><li><p>Be sure to use the correct reservoir and catheter for your pump.</p></li><li><p>Changing of the infusion set (tubing and needle) must be done according to the instructions in the product information supplied with the infusion set.</p></li><li><p>In the event of a hypoglycaemic episode, the infusion should be stopped until the episode is resolved. If repeated or severe low blood glucose levels occur, notify your doctor or clinic and consider the need to reduce or stop your insulin infusion.</p></li><li><p>A pump malfunction or obstruction of the infusion set can result in a rapid rise in glucose levels. If an interruption to insulin flow is suspected, follow the instructions in the product literature and if appropriate, notify your doctor or clinic.</p></li><li><p>When used with an insulin infusion pump, Liprolog should not be mixed with any other insulin.</p></li></ul><p>If you take more Liprolog than you need If you take more Liprolog than you need, a low blood sugar may occur. Check your blood sugar.<br/>If your blood sugar is low (mild hypoglycaemia), eat glucose tablets, sugar or drink a sugary drink. Then eat fruit, biscuits, or a sandwich, as your doctor has advised you and have some rest. This will often get you over mild hypoglycaemia or a minor insulin overdose. If you get worse and your breathing is shallow and your skin gets pale, tell your doctor at once. A glucagon injection can treat quite severe hypoglycaemia. Eat glucose or sugar after the glucagon injection. If you do not respond to glucagon, you will have to go to hospital. Ask your doctor to tell you about glucagon.</p><p>If you forget to use Liprolog If you take less Liprolog than you need, a high blood sugar may occur. Check your blood sugar</p><p>If hypoglycaemia (low blood sugar) or hyperglycaemia (high blood sugar) is not treated they can be very serious and cause headaches, nausea, vomiting, dehydration, unconsciousness, coma or even death (see A and B in section 4 Possible Side Effects ).</p><p>Three simple steps to avoid hypoglycaemia or hyperglycaemia are:</p><ul><li>Always keep spare syringes and a spare vial of Liprolog.</li><li>Always carry something to show you are diabetic.</li><li>Always carry sugar with you.</li></ul><p>If you stop using Liprolog. If you take less Liprolog than you need, a high blood sugar may occur. Do not change your insulin unless your doctor tells you to.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Systemic allergy is rare ( 1/10,000 to <1/1,000). The symptoms are as follows:</p><ul><li><p>rash over the whole body * blood pressure dropping</p></li><li><p>difficulty in breathing</p></li><li><p>heart beating fast</p></li><li><p>wheezing</p></li><li><p>sweating. If you think you are having this sort of insulin allergy with Liprolog, tell your doctor at once.</p></li></ul><p>Local allergy is common ( 1/100 to <1/10). Some people get redness, swelling or itching around the area of the insulin injection. This usually clears up in anything from a few days to a few weeks. If this happens to you, tell your doctor.</p><p>Lipodystrophy is uncommon ( 1/1,000 to <1/100). If you inject insulin too often at the same place, the fatty tissue may either shrink (lipoatrophy) or thicken (lipohypertrophy). Lumps under the skin may also be caused by build-up of a protein called amyloid (cutaneous amyloidosis). The insulin may not work very well if you inject into a lumpy area. Change the injection site with each injection to help prevent these skin changes.</p><p>Oedema (e.g. swelling in arms, ankles; fluid retention) has been reported, particularly at the start of insulin therapy or during a change in therapy to improve control of your blood glucose.</p><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>Common problems of diabetes</p><p>A.<br/>Hypoglycaemia<br/>Hypoglycaemia (low blood sugar) means there is not enough sugar in the blood. This can be caused if:</p><ul><li>you take too much Liprolog or other insulin;</li><li>you miss or delay meals or change your diet;</li><li>you exercise or work too hard just before or after a meal;</li><li>you have an infection or illness (especially diarrhoea or vomiting);</li><li>there is a change in your need for insulin; or</li><li>you have trouble with your kidneys or liver which gets worse.</li></ul><p>Alcohol and some medicines can affect your blood sugar levels.</p><p>The first symptoms of low blood sugar usually come on quickly and include the following:</p><ul><li><p>tiredness</p></li><li><p>rapid heartbeat</p></li><li><p>nervousness or shakiness * feeling sick</p></li><li><p>headache</p></li><li><p>cold sweat.</p></li></ul><p>While you are not confident about recognising your warning symptoms, avoid situations, e.g. driving a car, in which you or others would be put at risk by hypoglycaemia.</p><p>B.<br/>Hyperglycaemia and diabetic ketoacidosis Hyperglycaemia (too much sugar in the blood) means that your body does not have enough insulin. Hyperglycaemia can be brought about by:</p><ul><li>not taking your Liprolog or other insulin;</li><li>taking less insulin than your doctor tells you to;</li><li>eating a lot more than your diet allows; or</li><li>fever, infection or emotional stress.</li></ul><p>Hyperglycaemia can lead to diabetic ketoacidosis. The first symptoms come on slowly over many hours or days. The symptoms include the following:</p><ul><li><p>feeling sleepy</p></li><li><p>no appetite</p></li><li><p>flushed face</p></li><li><p>fruity smell on the breath</p></li><li><p>thirst</p></li><li><p>feeling or being sick.</p></li></ul><p>Severe symptoms are heavy breathing and a rapid pulse. Get medical help immediately.</p><p>C.<br/>Illness If you are ill, especially if you feel sick or are sick, the amount of insulin you need may change. Even when you are not eating normally, you still need insulin. Test your urine or blood, follow your sick rules , and tell your doctor.</p></div>
</text>
</section>
<section>
<title value="5. How to store liprolog"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store liprolog"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Before the first use store your Liprolog in a refrigerator (2 C 8 C). Do not freeze. Keep your vial in use in a refrigerator (2 C 8 C) or at room temperature up to 30 C and discard after 28 days. Do not put it near heat or in the sun.</p><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the label and the carton. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice it is coloured or it has solid pieces in it. You must use it only if it looks like water. Check this each time you inject yourself.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Liprolog 100 units/ml solution for injection in vial contains</p><ul><li>The active substance is insulin lispro. Insulin lispro is made in the laboratory by a recombinant DNA technology process. It is a changed form of human insulin and so is different from other human and animal insulins. Insulin lispro is closely related to human insulin which is a natural hormone made by the pancreas.</li><li>The other ingredients are m-cresol, glycerol, dibasic sodium phosphate 7 H2O, zinc oxide and water for injection. Sodium hydroxide or hydrochloric acid may have been used to adjust the acidity.</li></ul><p>What Liprolog looks like and contents of the pack Liprolog 100 units/ml, solution for injection is a sterile, clear, colourless, aqueous solution and contains 100 units of insulin lispro in each millilitre (100 units/ml) solution for injection. Each vial contains 1000 units (10 millilitres). Liprolog 100 units/ml, solution for injection in vial comes in a pack of 1 vial, 2 vials or a multipack of 5 x 1 vial. Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder and Manufacturer Liprolog 100 units/ml, solution for injection in vial is made by:</p><ul><li>Lilly S.A., Avda. de la Industria 30, 28108 Alcobendas, Madrid, Spain.</li></ul><p>The product licence is held by: Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands.</p><p>For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgique/Belgi /Belgien Eli Lilly Benelux S.A./N.V. T l/Tel: + 32-(0)2 548 84 Lietuva Eli Lilly Lietuva Tel. +370 (5) 2649<br/>" " . . -<br/>. + 359 2 491 41 Luxembourg/Luxemburg Eli Lilly Benelux S.A./N.V. T l/Tel: + 32-(0)2 548 84 esk republika ELI LILLY R, s.r.o. Tel: + 420 234 664 Magyarorsz g Lilly Hung ria Kft. Tel: + 36 1 328 5Danmark Eli Lilly Danmark A/S<br/>Tlf: +45 45 26 6Malta Charles de Giorgio Ltd. Tel: + 356 25600 Deutschland Lilly Deutschland GmbH Tel. + 49-(0) 6172 273 2Nederland Eli Lilly Nederland B.V.<br/>Tel: + 31-(0) 30 60 25 Eesti Eli Lilly Nederland B.V.<br/>Tel: +372 6817 Norge Eli Lilly Norge A.S.<br/>Tlf: + 47 22 88 18</p><ul><li>. . . .<br/>: +30 210 629 4 sterreich Eli Lilly Ges. m.b.H.<br/>Tel: + 43-(0) 1 711 Espa a Lilly S.A. Tel: + 34-91 663 50 Polska Eli Lilly Polska Sp. z o.o. Tel: +48 22 440 33 France Lilly France<br/>T l: +33-(0) 1 55 49 34 Portugal Lilly Portugal - Produtos Farmac uticos, Lda Tel: + 351-21-4126Hrvatska Eli Lilly Hrvatska d.o.o. Tel: +385 1 2350 Rom nia Eli Lilly Rom nia S.R.L. Tel: + 40 21 4023Ireland Eli Lilly and Company (Ireland) Limited Tel: + 353-(0) 1 661 4Slovenija Eli Lilly farmacevtska dru ba, d.o.o. Tel: +386 (0) 1 580 00 sland Icepharma hf.<br/>S mi + 354 540 8Slovensk republika Eli Lilly Slovakia s.r.o. Tel: + 421 220 663 Italia Eli Lilly Italia S.p.A. Tel: + 39- 055 42Suomi/Finland Oy Eli Lilly Finland Ab<br/>Puh/Tel: + 358-(0) 9 85 45<br/>Phadisco Ltd<br/>: +357 22 715Sverige Eli Lilly Sweden AB Tel: + 46-(0) 8 7378Latvija Eli Lilly (Suisse) S.A P rst vniec ba Latvij<br/>Tel: +371 67364United Kingdom (Northern Ireland) Eli Lilly and Company (Ireland) Limited Tel: + 353-(0) 1 661 4This leaflet was last revised in {MM/YYYY}.</li></ul><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp0c9b965fc8d8b37db9d00845bddc1040"/>
<resource>
<MedicinalProductDefinition>
<id value="mp0c9b965fc8d8b37db9d00845bddc1040"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp0c9b965fc8d8b37db9d00845bddc1040"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp0c9b965fc8d8b37db9d00845bddc1040</b></p><a name="mp0c9b965fc8d8b37db9d00845bddc1040"> </a><a name="hcmp0c9b965fc8d8b37db9d00845bddc1040"> </a><a name="mp0c9b965fc8d8b37db9d00845bddc1040-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/01/195/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Liprolog 100 units/ml, solution for injection in vial</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/01/195/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName
value="Liprolog 100 units/ml, solution for injection in vial"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
